FDA Endorses Further Studies on Ulcerative Colitis Drug from Lipid Therapeutics

FDA Endorses Further Studies on Ulcerative Colitis Drug from Lipid Therapeutics
Biopharmaceutical company Lipid Therapeutics has just announced the successful enrollment of the first batch of participants in a Phase III clinical trial for LT-02, the company’s first-in-class highly purified phosphatidylcholine pipeline product indicated for the treatment of ulcerative colitis that works to improve colon barrier function with delayed release technology. Dr. Falk Pharma GmbH is the company’s co-development partner in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *